Advocacy intelligence hub — real-time data for patient organizations
Paul Szabolcs — PHASE2
National Institute of Allergy and Infectious Diseases (NIAID) — PHASE1
Ensoma — PHASE1, PHASE2
Ensoma
Prime Medicine, Inc. — PHASE1, PHASE2
National Institute of Allergy and Infectious Diseases (NIAID) — PHASE1, PHASE2
National Institute of Allergy and Infectious Diseases (NIAID) — PHASE1
Great Ormond Street Hospital for Children NHS Foundation Trust — PHASE1, PHASE2
National Institute of Allergy and Infectious Diseases (NIAID) — EARLY_PHASE1
National Institute of Allergy and Infectious Diseases (NIAID) — PHASE1, PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Actimmune
(Interferon gamma 1-b)Orphan drugHorizon Therapeutic Ireland DAC
Interferon gamma [EPC]
12.1 Mechanism of Action Interferons bind to specific cell surface receptors and initiate a sequence of intracellular events that lead to the transcri...
Donald B. Kohn, MD, D.D.S
University of California, Los Angeles
📍 NEW HAVEN, CT
Paul Szabolcs, MD
UPMC Children's Hospital of Pittsburgh
📍 Pittsburgh, Pennsylvania
Elizabeth M Kang, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
📍 Bethesda, Maryland
Suk S De Ravin, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
📍 Bethesda, Maryland
Joanne Kurtzberg, MD, M.D
Duke University
📍 DURHAM, NC
Harry L Malech, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
📍 Bethesda, Maryland